Omeros Corporation has disclosed that the Committee for Medicinal Products for Human Use adopted a negative opinion on the European marketing authorization application for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA. The biotechnology firm intends to request a re-examination and seek an independent Ad Hoc Expert Group review after narsoplimab received United States approval under the Yartemlea name in December 2025.
The setback places the quality and interpretation of the narsoplimab evidence package at the centre of the European regulatory process. The principal challenge is no longer whether TA-TMA represents a severe unmet medical need or whether MASP-2 inhibition has a plausible biological rationale. Omeros Corporation must now persuade European reviewers that the available clinical results demonstrate a treatment effect that can be separated from supportive care, concomitant medications, patient selection and the natural variability of a complex post-transplant complication.
Why the CHMP refusal is a scientific evidence problem rather than a routine regulatory delay
The negative opinion is materially more serious than a request for additional administrative information or a short extension of the review timetable. European regulators concluded that the application did not contain sufficient evidence to establish the effectiveness of narsoplimab, raising questions about the pivotal study design, changes made during the study, the efficacy measures used, dose selection and the reliability of external survival comparisons.
That distinction matters because the concerns affect the foundations of the benefit assessment. A regulator can often resolve manufacturing, labelling or risk-management questions through commitments, inspections or narrower product information. Questions about whether a therapy itself caused the observed clinical improvement are harder to address without a randomized comparator, prospectively defined analysis or additional confirmatory evidence.
Safety was not presented as the sole or dominant reason for the refusal. Instead, the central issue was whether the results were interpretable enough to demonstrate efficacy and establish a favourable benefit-risk profile. That leaves Omeros Corporation with a demanding task during re-examination because the firm must defend the existing evidence rather than simply add a new pivotal trial to the current review.
Why the same narsoplimab data produced different regulatory conclusions in the United States and Europe
The regulatory divergence is particularly significant because the European application relied on substantially the same clinical programme that supported United States approval. Narsoplimab became the first approved TA-TMA treatment in the United States for adults and children aged two years and older after regulators considered evidence from a 28-patient, single-arm study and additional expanded-access experience.
The pivotal study produced a 61% TA-TMA response rate using a composite assessment that included improvements in laboratory markers and organ function or freedom from transfusion. Expanded-access data provided further experience in adult and pediatric patients, while comparative survival analyses attempted to place narsoplimab outcomes against patients who had not received the treatment.
Those findings established a sufficient basis for United States authorization, but European regulators reached a different conclusion about causal certainty. The absence of a randomized control group meant that outcomes could not be cleanly separated from other medications, changes in transplant care or differences between treated patients and historical controls. The disagreement therefore reflects different judgments about how much uncertainty can be accepted in a rare, life-threatening condition where controlled trials are difficult to conduct.
The United States approval remains commercially and clinically important, but it does not neutralize the European concerns. Cross-regulatory precedent can strengthen an applicant’s argument, especially when the underlying disease and treatment population are the same. It does not require another regulator to accept the same endpoint, external comparator or interpretation of benefit.
How the uncontrolled trial design became the central obstacle for European authorization
Single-arm trials are common in rare diseases, aggressive cancers and conditions with limited treatment options. They can support approval when the natural history is sufficiently predictable, the treatment effect is large, the endpoint is objective and alternative explanations are unlikely. TA-TMA complicates that model because diagnosis, severity, supportive care and outcomes can differ considerably across transplant centres.
Patients in the narsoplimab study also received other therapies, making it difficult to attribute changes in platelet counts, lactate dehydrogenase, organ function or transfusion requirements solely to MASP-2 inhibition. Even an apparently meaningful response rate may be challenged when the endpoint combines laboratory and clinical components that can be affected by several interventions.
The European review also raised concerns about study modifications and dose selection. Such issues can weaken confidence that the observed results emerged from a stable, prospectively defined trial rather than an analysis framework that evolved as data accumulated. They also create practical questions about whether the selected dosing regimen consistently produces the intended biological and clinical effects across adults and children.
External controls were intended to address the lack of randomization, but they introduced another layer of uncertainty. Differences in diagnostic criteria, disease severity, transplant practices, timing of treatment, organ involvement and access to supportive care can distort comparisons even when statistical matching methods are used. The survival analyses may remain clinically encouraging, but European authorization requires confidence that the measured difference is attributable to narsoplimab rather than residual differences between populations.
Why severe unmet need in TA-TMA strengthens the case but cannot replace proof of treatment effect
TA-TMA is a serious complication of hematopoietic stem cell transplantation in which endothelial injury and complement activation contribute to small-vessel damage, thrombosis and organ dysfunction. Severe disease can involve the kidneys, gastrointestinal system, lungs, cardiovascular system and central nervous system, with mortality rising sharply in high-risk patients.
Europe currently lacks an approved therapy specifically for TA-TMA. Clinical management has historically depended on supportive care, modification of contributing transplant medications and off-label approaches that may include complement-directed therapies or other interventions selected according to individual patient characteristics and institutional practice.
This unmet need gives Omeros Corporation a powerful clinical argument, but urgency cannot substitute for evidence. Regulators must still determine whether approval would improve outcomes, expose vulnerable transplant recipients to ineffective treatment or redirect patients from other potentially useful interventions. The difficulty is amplified because severely ill patients frequently receive several treatments at the same time, making uncontrolled evidence especially vulnerable to confounding.
The mechanistic rationale for narsoplimab remains relevant. The monoclonal antibody inhibits MASP-2, an effector enzyme of the lectin pathway of complement, while preserving activity in the classical and alternative pathways. That selectivity could theoretically reduce endothelial injury without reproducing every consequence associated with broader complement inhibition. However, a credible mechanism supports clinical development rather than proving clinical effectiveness, and European reviewers concluded that the submitted results did not sufficiently confirm the proposed treatment effect.
Why the proposed pediatric indication now faces a separate dosing and evidence challenge
Omeros Corporation sought a European indication covering adults and children from two years of age, matching the broad population authorized in the United States. The pediatric component is now a distinct vulnerability because the European review found insufficient data to support the proposed dose or adequately assess effectiveness and safety in children.
Pediatric rare-disease programmes routinely depend on extrapolation from adults, particularly when recruitment is difficult and the disease mechanism is expected to be similar. That strategy becomes less reliable when adult efficacy itself remains uncertain. Regulators cannot confidently extend a treatment effect across age groups when the original treatment effect has not been established to their satisfaction.
The expanded-access programme included pediatric experience, but compassionate-use evidence is difficult to interpret. Treatment decisions are not randomized, follow-up can vary, patients may enter at different stages of disease and clinical data collection is less uniform than in a controlled trial. Those limitations do not make the observations irrelevant, but they restrict how much regulatory weight they can carry.
A successful re-examination could theoretically result in a narrower indication, more restrictive population or additional post-authorization obligations. However, a narrower label would still require the existing dataset to identify a subgroup with a sufficiently persuasive benefit-risk profile. Without new evidence, any restriction must be supported by analyses already available when the initial opinion was adopted.
What Omeros can realistically achieve through the CHMP re-examination
Omeros Corporation can notify the European Medicines Agency of its intention to seek re-examination within 15 days of receiving the opinion. Detailed grounds can then be submitted within 60 days, after which different rapporteurs reconsider the disputed scientific points and the Committee for Medicinal Products for Human Use completes the re-examination within a further 60-day assessment period.
The requested Ad Hoc Expert Group could give Omeros Corporation an opportunity to place the evidence before specialists with direct knowledge of TA-TMA, hematopoietic cell transplantation, disease heterogeneity and the practical barriers to randomized trials. Expert input may help reviewers evaluate whether the observed responses and survival outcomes are clinically credible despite the methodological weaknesses.
The process nevertheless has an important limitation. Re-examination is based on scientific data that were available when the original opinion was adopted. It is not a route for introducing an entirely new confirmatory clinical programme. Omeros Corporation must therefore show that the committee gave insufficient weight to existing evidence, interpreted the limitations too conservatively or failed to account adequately for the disease context.
Re-examinations can overturn negative opinions, but they are not routine appeals in which unmet need alone produces a different result. The strongest case would require a disciplined response to each objection, including the effect of concomitant therapies, endpoint validity, study changes, dose justification, external-control comparability, pediatric extrapolation and biological evidence supporting MASP-2 inhibition.
How the European setback changes the commercial outlook for Yartemlea and Omeros Corporation
The negative opinion delays the possibility of a centralized authorization covering European Union and European Economic Area markets. That removes a near-term expansion opportunity at a time when Omeros Corporation is attempting to establish Yartemlea as a commercial rare-disease product rather than a development-stage asset.
The United States launch provides an important counterweight. Commercial distribution began in January 2026, and Omeros Corporation reported $9.9 million in first-quarter net product sales. Reimbursement infrastructure has also been developing, including a permanent product-specific J-code scheduled to become effective in July 2026, which could simplify billing and payment processes in the United States.
The market reaction showed that investors still assigned meaningful value to European approval. Omeros Corporation shares closed at $8.67 on June 26, falling approximately 19% after the negative opinion became public. The decline suggests that investors viewed re-examination as uncertain rather than assuming that United States approval would lead automatically to a European reversal.
European compassionate use may continue during the regulatory process, with children receiving priority, but it is not a substitute for commercial authorization. Supply and access constraints limit the number of patients who can receive treatment, while hospitals may face operational and funding barriers that would be less restrictive under a formal marketing authorization and reimbursement pathway.
The setback does not invalidate the United States franchise, but it increases geographic concentration. Near-term commercial performance will depend more heavily on United States transplant-centre adoption, payer coverage, diagnosis rates and physician confidence while European revenue remains deferred and uncertain.
What transplant clinicians and regulatory observers will watch before the next CHMP decision
The most important question is whether Omeros Corporation can demonstrate that the clinical response and survival signals remain persuasive after accounting for concomitant medications, population differences and changes in care. Reviewers will also examine whether the composite response endpoint captures a meaningful improvement in TA-TMA rather than temporary changes in laboratory values.
The robustness of the external-control analyses will receive particular attention. Matching methods can improve comparability, but they cannot eliminate unmeasured differences. The re-examination will need to show that diagnostic criteria, risk status, organ involvement, treatment timing and follow-up were sufficiently aligned to support a credible survival comparison.
Dose selection and pediatric extrapolation are likely to remain separate decision points. A positive outcome for adults would not necessarily guarantee approval across the full pediatric population, especially if pharmacokinetic, safety or response evidence remains limited.
The broader industry lesson is that rare-disease approvals based on uncontrolled evidence remain vulnerable to regulatory divergence. A therapy can possess strong biological rationale, encouraging response data, a supportive external comparison and approval in one major market while still failing another regulator’s standard for causal evidence.
Re-examination gives Omeros Corporation a credible but narrow path to reversing the opinion. The disease severity, lack of an approved European treatment and consistency of several clinical datasets support continued review. However, the objections address trial interpretability rather than a misunderstanding that can be corrected through presentation alone. Unless the expert review materially changes how the existing data are weighed, the absence of randomized evidence and the weaknesses identified in the external comparisons may continue to prevent a positive European benefit-risk conclusion.
